Lanreotid Advanz Pharma 60 mg

Lanreotid Advanz Pharma 60 mg is a medicine authorised by Swissmedic under authorisation number 70157. The authorisation holder is Advanz Pharma Specialty Medicine Switzerland GmbH. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 18 August 2026 and the authorisation is limited until 17 August 2031. ATC code H01CB03 places the medicine in the group Pituitary and hypothalamic hormones and analogues.

  • Dispensing category A
  • Authorisation number 70157
  • ATC H01CB03
  • Synthetic medicines
Authorisation data
Authorisation number70157
NameLanreotid Advanz Pharma 60 mg
Full nameLanreotid Advanz Pharma 60 mg, Depot-Injektionslösung in einer Fertigspritze
Authorisation holderAdvanz Pharma Specialty Medicine Switzerland GmbH
Medicinal product codeSynthetic medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeH01CB03
First authorisation18 August 2026
Authorisation validity17 August 2031
Strengths
No.NameDispensing categoryAuthorisation date
1Lanreotid Advanz Pharma 60 mg, Depot-Injektionslösung in einer FertigspritzeA18 August 2026
2Lanreotid Advanz Pharma 90 mg, Depot-Injektionslösung in einer FertigspritzeA18 August 2026
3Lanreotid Advanz Pharma 120 mg, Depot-Injektionslösung in einer FertigspritzeA18 August 2026

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
11Fertigspritze(n)H01CB0307.16.2.A
21Fertigspritze(n)H01CB0307.16.2.A
31Fertigspritze(n)H01CB0307.16.2.A

Scroll the table sideways

Medicines in the same ATC group

Other medicines from this authorisation holder

Frequently asked questions

Is Lanreotid Advanz Pharma 60 mg authorised in Switzerland?

Yes. Lanreotid Advanz Pharma 60 mg is authorised by Swissmedic under authorisation number 70157, data as of 01 September 2026. The authorisation is limited until 17 August 2031.

Which dispensing category does Lanreotid Advanz Pharma 60 mg have?

Lanreotid Advanz Pharma 60 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Lanreotid Advanz Pharma 60 mg?

The authorisation holder is Advanz Pharma Specialty Medicine Switzerland GmbH. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com